UFIのチャート
UFIの企業情報
| symbol | UFI |
|---|---|
| 会社名 | Unifi Inc. （UNIFI INC） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 繊維_革製品 一般消費財（Consumer Products） |
| 概要 | ユニファイ（Unifi Inc.）は製造会社である。同社は、コモディティヤーン、特殊ヤーン、およびプレミア付加価値（PVA）ヤーンを処理し、販売している。同社は、ポリエステルセグメント、ナイロンセグメント及び国際セグメントの3つのセグメントを通じて事業を行っている。同社のポリエステル製品には、ポリエステルポリマービーズ（チップ）、半延伸糸（POY）、テクスチャード、溶液およびパッケージ染色、撚糸、ビームおよび巻き取り糸が含まれる。ポリエステル製品はリサイクル品種で販売される。リサイクル品は、消費前の糸屑およびペットボトルを含む消費後の廃棄物の両方から製造される。同社のナイロン製品には、テクスチャー加工、溶液染色、スパンデックス被覆製品が含まれる。同社の製品には、REPREVE、Sorbtek、Reflexx、aio、AugustaおよびA.M.Yが含まれる。同社の製品の主な地域市場は、北米、中米、南米、アジアにある。 ユニフィは、米国の糸製造会社。主に、ポリエステルとナイロン製糸を｢SORBTEK｣、｢A.M.Y.｣、｢MYNX｣、｢INHIBIT｣、｢マイクロビスタ｣などのブランド名で製造、販売する。同社の加工糸は、主に衣料品、靴下、家庭装飾品、自動車の内装用布などに使用される。事業は、ポリエステル、ナイロン、インタ―ナショナルの3部門で構成。 Unifi, Inc. is a global textile solutions provider and one of the world's leading innovators in manufacturing synthetic and recycled performance fibers. Through REPREVE®, one of Unifi's proprietary technologies and the global leader in branded recycled performance fibers, Unifi has transformed more than 23 billion plastic bottles into recycled fiber for new apparel, footwear, home goods and other consumer products. The Company's proprietary PROFIBER™ technologies offer increased performance, comfort, and style advantages, enabling customers to develop products that perform, look, and feel better. Unifi continually innovates technologies to meet consumer needs in moisture management, thermal regulation, antimicrobial protection, UV protection, stretch, water resistance, and enhanced softness. Unifi collaborates with many of the world's most influential brands in the sports apparel, fashion, home, automotive, and other industries. |
| 本社所在地 | 7201 West Friendly Avenue Greensboro NC 27410 USA |
| 代表者氏名 | Thomas H. Caudle |
| 代表者役職名 | Principal Executive Officer President Chief Executive Officer Chief Operating Officer Director |
| 電話番号 | +1 919-294-4410 |
| 設立年月日 | 25204 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 3100人 |
| url | － |
| nasdaq_url | |
| adr_tso | |
| EBITDA | （百万ドル） 38.87400 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | （百万ドル） 365.68870 |
| 売上高 | （百万ドル） 696.51400 |
| 企業価値(EV) | （百万ドル） 464.99870 |
| 当期純利益 | （百万ドル） 14.59300 |
| 決算概要 | BRIEF: For the 27 weeks ended 30 December 2018 Unifi Inc. revenues increased 5% to $349.3M. Net income before extraordinary items decreased 93% to $1.2M. Revenues reflect International segment increase of 11% to $110.6M Polyester segment increase of 4% to $185.9M All other segment increase of 9% to $2.2M. Net income was offset by Polyester segment income decrease of 33% to $16.9M Nylon segment income decrease of 30% to $5.2M. |
UFIのテクニカル分析
UFIのニュース
New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis 2023/03/04 10:41:00 Benzinga
Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ulcerative colitis achieved clinical remission, clinical response, and/or demonstrated endoscopic improvement at four years SPRING HOUSE, Pa. , March 4, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA ® (ustekinumab) through five years in adults with moderately to severely active Crohn''s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC. 1,2 These data are a part of Janssen''s 22 oral and poster presentations at the 18 th Congress of the European Crohn''s and Colitis Organization (ECCO), taking place in Copenhagen, Denmark , March 1-4 . "These data reinforce the known efficacy and safety profile of STELARA, and demonstrate it can be an effective long-term treatment option for patients living with moderately to severely active ulcerative colitis," said UNIFI study author Waqqas Afif , M.D., Associate Professor, Department of Medicine, Division of Experimental Medicine and Division of Gastroenterology at McGill University Health Centre in Montreal, Canada . a "Importantly, clinical and endoscopic outcomes reinforce the durable efficacy of STELARA, as we remain committed to developing therapies that provide patients with lasting remission." Final STELARA long-term pooled safety analysis (Oral presentation OP39): 1 A final pooled safety analysis of six Phase 2/3 IBD studies included 2,575 patients treated with STELARA and a total of 4,826 patient-years (PY) of follow-up.
UNIFI, Makers of REPREVE, Publishes New Sustainability Report - Company Aims to Transform 50 Billion Plastic Bottles by 2025 2023/02/22 14:00:00 Wallstreet:Online
Unifi, Inc. (NYSE: UFI) (together with its consolidated subsidiaries, “UNIFI”), makers of REPREVE and one of the world’s leading innovators in recycled and synthetic yarns, today released its Sustainability Report for fiscal 2022. The Report provides expanded insight into UNIFI’s industry leading sustainability strategy and the Company’s responsible approach to creating long-term value
Weak Apparel Demand Continues To Unravel Unifi’s Operating Results (NYSE:UFI) 2023/02/12 07:30:57 Seeking Alpha
Excess inventory in clothing retailers is crushing near-term demand for Unifi''s yarns. Read more to see why I''m still bullish on UFI stock.
Unifi, Inc. (UFI) Q2 2023 Earnings Call Transcript 2023/02/02 18:57:04 Seeking Alpha
Unifi, Inc. [UFI] Q2 2023 Earnings Conference Call February 2, 2023 8:30 AM ETCompany ParticipantsAlbert Carey - Executive ChairmanEddie Ingle - CEOCraig Creaturo - CFOA.J.
CJS Securities Upgrades Unifi Inc to Market Outperform 2023/02/02 17:26:02 Investing.com
https://www.investing.com/news/pro/cjs-securities-upgrades-unifi-inc-to-market-outperform-432SI-2994388
New STELARA® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis 2023/03/04 10:41:00 Benzinga
Final cumulative pooled IBD safety data support the longstanding safety profile of STELARA across all IBD approved indications Additional long term extension data demonstrate more than half of STELARA-treated patients with ulcerative colitis achieved clinical remission, clinical response, and/or demonstrated endoscopic improvement at four years SPRING HOUSE, Pa. , March 4, 2023 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA ® (ustekinumab) through five years in adults with moderately to severely active Crohn''s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC. 1,2 These data are a part of Janssen''s 22 oral and poster presentations at the 18 th Congress of the European Crohn''s and Colitis Organization (ECCO), taking place in Copenhagen, Denmark , March 1-4 . "These data reinforce the known efficacy and safety profile of STELARA, and demonstrate it can be an effective long-term treatment option for patients living with moderately to severely active ulcerative colitis," said UNIFI study author Waqqas Afif , M.D., Associate Professor, Department of Medicine, Division of Experimental Medicine and Division of Gastroenterology at McGill University Health Centre in Montreal, Canada . a "Importantly, clinical and endoscopic outcomes reinforce the durable efficacy of STELARA, as we remain committed to developing therapies that provide patients with lasting remission." Final STELARA long-term pooled safety analysis (Oral presentation OP39): 1 A final pooled safety analysis of six Phase 2/3 IBD studies included 2,575 patients treated with STELARA and a total of 4,826 patient-years (PY) of follow-up.
UNIFI, Makers of REPREVE, Publishes New Sustainability Report - Company Aims to Transform 50 Billion Plastic Bottles by 2025 2023/02/22 14:00:00 Wallstreet:Online
Unifi, Inc. (NYSE: UFI) (together with its consolidated subsidiaries, “UNIFI”), makers of REPREVE and one of the world’s leading innovators in recycled and synthetic yarns, today released its Sustainability Report for fiscal 2022. The Report provides expanded insight into UNIFI’s industry leading sustainability strategy and the Company’s responsible approach to creating long-term value
Weak Apparel Demand Continues To Unravel Unifi’s Operating Results (NYSE:UFI) 2023/02/12 07:30:57 Seeking Alpha
Excess inventory in clothing retailers is crushing near-term demand for Unifi''s yarns. Read more to see why I''m still bullish on UFI stock.
Unifi, Inc. (UFI) Q2 2023 Earnings Call Transcript 2023/02/02 18:57:04 Seeking Alpha
Unifi, Inc. [UFI] Q2 2023 Earnings Conference Call February 2, 2023 8:30 AM ETCompany ParticipantsAlbert Carey - Executive ChairmanEddie Ingle - CEOCraig Creaturo - CFOA.J.
CJS Securities Upgrades Unifi Inc to Market Outperform 2023/02/02 17:26:02 Investing.com
https://www.investing.com/news/pro/cjs-securities-upgrades-unifi-inc-to-market-outperform-432SI-2994388
Unifi Stock: Sharp Downturn In Orders Doesn’t Unravel Long-Term Story 2022/12/01 03:35:13 Seeking Alpha
Unifi has seen a sharp downturn in volumes as apparel companies have cut orders. See why I still believe there is a bullish case to be made for UFI stock.
Unifi announces major expansion of Textile Takeback program 2022/11/28 13:34:40 Seeking Alpha
Unifi (UFI) announced a major expansion of its innovative Textile Takeback program
UNIFI, Makers of REPREVE®, Announces Major Expansion of Textile Takeback™ 2022/11/28 13:00:00 Business Wire
GREENSBORO, N.C.--(BUSINESS WIRE)--Today, Unifi Inc. (NYSE: UFI), makers of REPREVE® and one of the world’s leading innovators in recycled and synthetic yarns, announced a major expansion of its innovative Textile Takeback™ program. The initiative is designed to collect and recycle polyester-based fabric waste, including both pre- and post-consumer fabrics, and transform it into REPREVE® – the leading recycled performance fiber that powers top brands and sustainable goods worldwide. With millio
UNIFI, Makers of REPREVE, Announces Major Expansion of Textile Takeback 2022/11/28 13:00:00 Wallstreet:Online
Today, Unifi Inc. (NYSE: UFI), makers of REPREVE and one of the world’s leading innovators in recycled and synthetic yarns, announced a major expansion of its innovative Textile Takeback program. The initiative is designed to collect and recycle polyester-based fabric waste, including both pre- and post-consumer fabrics, and transform it into REPREVE – the leading recycled performance fiber